Objective To compare the effects of treatments for coronavirus disease 2019 (covid-19).
Design Living systematic review and network meta-analysis. Data sources WHO covid-19 …

Summary COVID-19, caused by SARS-CoV-2, is characterised by a broad spectrum of
symptom severity that requires varying amounts of care according to the different stages of …

As of December 2022, there have been over 642 million confirmed cases of COVID-19 (10).
The pandemic has thus far claimed approximately 6.62 million lives (10). Vaccination is …

Background: No effective oral therapy exists for early coronavirus disease 2019 (COVID-19).
Objective: To investigate whether hydroxychloroquine could reduce COVID-19 severity in …

Objective To evaluate the efficacy and safety of antiviral antibody therapies and blood
products for the treatment of novel coronavirus disease 2019 (covid-19). Design Living …

Updates This is the second version (first update) of the living systematic review, replacing
the previous version (available as a data supplement). When citing this paper please …

Background: Living practice guidelines are increasingly being used to ensure that
recommendations are responsive to rapidly emerging evidence. Objective: To develop a …

Coronaviruses are important human and animal pathogens. At the end of 2019, a novel
coronavirus was identified as the cause of a cluster of pneumonia cases in Wuhan, a city in …

Background Atopic dermatitis (AD) is an inflammatory skin condition with multiple systemic
treatments and uncertainty regarding their comparative impact on AD outcomes. Objective …

Late-stage modification of drug molecules is a fast method to introduce diversity into the
already biologically active scaffold. A notable number of analogs of mefloquine, chloroquine …